Nucleic acids encoding plasma kallikrein binding proteins

Patent metadata

Field	Value
Publication number	US-11401346-B2
Application number	US-201916445304-A
Country	US
Kind code	B2
Filing date	Jun 19, 2019
Priority date	Jan 6, 2011
Publication date	Aug 2, 2022
Grant date	Aug 2, 2022

Abstract

Plasma kallikrein binding proteins and methods of using such proteins are described.

First claim

We claim:

1. A nucleic acid(s) encoding an antibody that binds plasma kallikrein, wherein the antibody comprises a heavy chain comprising a heavy chain variable region and a heavy chain constant region and a light chain comprising a light chain variable region and a light chain constant region, and wherein the antibody is selected from the group consisting of:
(i) an antibody comprising a heavy chain variable region comprising a complementary determining region (CDR1) set forth as HYIMM (SEQ ID NO: 166), a CDR2 set forth as GIYSSGGITVYADSVKG (SEQ ID NO: 167), and a CDR3 set forth as RRIGVPRRDEFDI (SEQ ID NO: 1171) or RRTGVPRWDDFDI (SEQ ID NO: 1177); and a light chain variable region comprising a CDR1 set forth as RASQSISSWLA (SEQ ID NO: 1172), a CDR2 set forth as KASTLES (SEQ ID NO: 1173), and a CDR3 set forth as QQYNTYWT (SEQ ID NO: 1174);
(ii) an antibody comprising a heavy chain variable region comprising a CDR1 set forth as HYIMM (SEQ ID NO: 166), a CDR2 set forth as GIYSSGGITVYADSVKG (SEQ ID NO: 167), and a CDR3 set forth as RRTGIPRRDAFDI (SEQ ID NO: 1183); and a light chain variable region comprising a CDR1 set forth as RASQSISSWLA (SEQ ID NO: 1172), a CDR2 set forth as KASTLES (SEQ ID NO: 1173), and a CDR3 set forth as QQYNTYWT (SEQ ID NO: 1174);
(iii) an antibody comprising a heavy chain variable region comprising a CDR1 set forth as HYLMT (SEQ ID NO: 1807), a CDR2 set forth as YISPSGGHTIYADSVKG (SEQ ID NO: 1814), and a CDR3 set forth as VARGIAARSRTSYFDY (SEQ ID NO: 1821); and a light chain variable region comprising a CDR1 set forth as RTSQFVNSNYLA (SEQ ID NO: 1822), a CDR2 set forth as GASSRAT (SEQ ID NO: 1823), and a CDR3 set forth as QQSSRTPWT (SEQ ID NO: 1824);
(iv) an antibody comprising a heavy chain variable region comprising a CDR1 set forth as HYLMT (SEQ ID NO: 1807), a CDR2 set forth as YISPSGGHTIYADSVKG (SEQ ID NO: 1814), and a CDR3 set forth as VARGIAARSRTSYFDY (SEQ ID NO: 1821); and a light chain variable region comprising a CDR1 set forth as RTSQFVNSNYLA (SEQ ID NO: 1822), a CDR2 set forth as GASSRAT (SEQ ID NO: 1823), and a CDR3 set forth as QQSSRTPWT (SEQ ID NO: 1824);
(v) an antibody comprising a heavy chain variable region comprising a CDR1 set forth as HYLMT (SEQ ID NO: 1807), a CDR2 set forth as YISPSGGHTIYADSVKG (SEQ ID NO: 1814), and a CDR3 set forth as VARGIAARSRTSYFDY (SEQ ID NO: 1821); and a light chain variable region comprising a CDR1 set forth as RTSQFVNSNYLA (SEQ ID NO: 1822), a CDR2 set forth as GASSRAT (SEQ ID NO: 1823), and a CDR3 set forth as QQSSRTPWT (SEQ ID NO: 1824);
(vi) an antibody comprising a heavy chain variable region comprising a CDR1 set forth as HYLMT (SEQ ID NO: 1807), a CDR2 set forth as YISPSGGHTIYADSVKG (SEQ ID NO: 1814), and a CDR3 set forth as VARGIAARSRTSYFDY (SEQ ID NO: 1821); and a light chain variable region comprising a CDR1 set forth as RASQGISSYLA (SEQ ID NO: 151), a CDR2 set forth as AASTLQS (SEQ ID NO: 152), and a CDR3 set forth as QQLNSYPLT (SEQ ID NO: 153);
(vii) an antibody comprising a heavy chain variable region comprising a CDR1 set forth as AYSMI (SEQ ID NO: 124), a CDR2 set forth as YIRPSGGRTTYADSVKG (SEQ ID NO: 125), and a CDR3 set forth as GGLLLWFRELKSNYFDY (SEQ ID NO: 126); and a light chain variable region comprising a CDR1 set forth as RASQPIDNYLN (SEQ ID NO: 169), a CDR2 set forth as AASRLQS (SEQ ID NO: 170), and a CDR3 set forth as QQSYTVPYT (SEQ ID NO: 171);
(viii) an antibody comprising a heavy chain variable region comprising a CDR1 set forth as AYSMI (SEQ ID NO: 124), a CDR2 set forth as YIRPSGGRTTYADSVKG (SEQ ID NO: 125), and a CDR3 set forth as GGLLLWNRELKSNYFDY (SEQ ID NO: 192); and a light chain variable region comprising a CDR1 set forth as RASQPIDNYLN (SEQ ID NO: 193), a CDR2 set forth as AASRLQS (SEQ ID NO: 170), and a CDR3 set forth as QQSYTVPYT (SEQ ID NO: 171);
(ix) an antibody comprising a heavy chain variable region comprising a CDR1 set forth as AYSMI (SEQ ID NO: 124), a CDR2 set forth as YIRPSGGRTTYADSVKG (SEQ ID NO: 125), and a CDR3 set forth as GGLLLWARELKSNYFDY (SEQ ID NO: 216); and a light chain variable region comprising a CDR1 set forth as RASQPIDNYLN (SEQ ID NO: 193), a CDR2 set forth as AASRLQS (SEQ ID NO: 170), and a CDR3 set forth as QQSYTVPYT (SEQ ID NO: 171);
(x) an antibody comprising a heavy chain variable region comprising a CDR1 set forth as HYLMT (SEQ ID NO: 154), a CDR2 set forth as YISPSGGHTIYADSVKG (SEQ ID NO: 155), and a CDR3 set forth as VGQGIRGRSRTSYFAQ (SEQ ID NO: 1815); and a light chain variable region comprising a CDR1 set forth as RTSQFVNSNYLA (SEQ ID NO: 1816), a CDR2 set forth as GASSRAT (SEQ ID NO: 1817), and a CDR3 set forth as QQSSRTPWT (SEQ ID NO: 1818);
(xi) an antibody comprising a heavy chain variable region comprising a CDR1 set forth as DYMMA (SEQ ID NO: 1819), a CDR2 set forth as SIVPSGGHTHYADSVKG (SEQ ID NO: 1820), and a CDR3 set forth as VARGIAARSRTSYFDY (SEQ ID NO: 1821); and a light chain variable region comprising a CDR1 set forth as RTSQFVNSNYLA (SEQ ID NO: 1816), a CDR2 set forth as GASSRAT (SEQ ID NO: 1817), and a CDR3 set forth as QQSSRTPWT (SEQ ID NO: 1818);
(xii) an antibody comprising a heavy chain variable region comprising a CDR1 set forth as HYLMT (SEQ ID NO: 154), a CDR2 set forth as YISPSGGHTIYADSVKG (SEQ ID NO: 155), and a CDR3 set forth as VAQGIAARSRTSSVDQ (SEQ ID NO: 1827); and a light chain variable region comprising a CDR1 set forth as RTSQFVNSNYLA (SEQ ID NO: 1816), a CDR2 set forth as GASSRAT (SEQ ID NO: 1817), and a CDR3 set forth as QQSSRTPWT (SEQ ID NO: 1818);
(xiii) an antibody comprising a heavy chain variable region comprising a CDR1 set forth as HYLMT (SEQ ID NO: 154), a CDR2 set forth as YISPSGGHTIYADSVKG (SEQ ID NO: 155), and a CDR3 set forth as VAQGISARSRTSYFDY (SEQ ID NO: 1863); and a light chain variable region comprising a CDR1 set forth as RTSQFVNSNYLA (SEQ ID NO: 1816), a CDR2 set forth as GASSRAT (SEQ ID NO: 1817), and a CDR3 set forth as QQSSRTPWT (SEQ ID NO: 1818);
(xiv) an antibody comprising a heavy chain variable region comprising a CDR1 set forth as HYIMM (SEQ ID NO: 166), a CDR2 set forth as GIYSSGGITVYADSVKG (SEQ ID NO: 167), and a CDR3 set forth as RRIGVPRRDSFDM (SEQ ID NO: 1189); and a light chain variable region comprising a CDR1 set forth as RASQSISSWLA (SEQ ID NO: 1172), a CDR2 set forth as KASTLES (SEQ ID NO: 1173), and a CDR3 set forth as QQYNTYWT (SEQ ID NO: 1174);
(xv) an antibody comprising a heavy chain variable region comprising a CDR1 set forth as IYSMH (SEQ ID NO: 1157), a CDR2 set forth as SIYPSRGMTWYADSVKG (SEQ ID NO: 1158), and a CDR3 set forth as RRTGIPRRDAFDI (SEQ ID NO: 1159); and a light chain variable region comprising a CDR1 set forth as RASQSISSWLA (SEQ ID NO: 1172), a CDR2 set forth as KASTLES (SEQ ID NO: 1173), and a CDR3 set forth as QQYNTYWT (SEQ ID NO: 1174);
(xvi) an antibody comprising a heavy chain variable region comprising a CDR1 set forth as HYIMM (SEQ ID NO: 166), a CDR2 set forth as GIYSSGGITVYADSVKG (SEQ ID NO: 167), and a CDR3 set forth as RRTGVPRRDEFDI (SEQ ID NO: 1201); and a light chain variable region comprising a CDR1 set forth as RASQSISSWLA (SEQ ID NO: 1172), a CDR2 set forth as KASTLES (SEQ ID NO: 1173), and a CDR3 set forth as QQYNTYWT (SEQ ID NO: 1174);
(xvii) an antibody comprising a heavy chain variable region comprising a CDR1 set forth as WYTMV (SEQ ID NO: 52), a CDR2 set forth as YIYPSGGATFYADSVKG (SEQ ID NO: 71), and a CDR3 set forth as GSYDYIWGFYSDH (SEQ ID NO: 72); and a light chain variable region comprising a CDR1 set forth as SGNKLGDKYVA (SEQ ID NO: 2361), a CDR2 set forth as QDTKRPS (SEQ ID NO: 2362), and a CDR3 set forth as QAWDSSIVI (SEQ ID NO: 2363);
(xviii) an antibody comprising a heavy chain variable region comprising a CDR1 set forth as HYRMS (SEQ ID NO: 94), a CDR2 set forth as SIYPSGGRTVYADSVKG (SEQ ID NO: 95), and a CDR3 set forth as DKFEWRLLFRGIGNDAFDI (SEQ ID NO: 96); and a light chain variable region comprising a CDR1 set forth as SGDKLGDKY

Assignees

• Takeda Pharmaceuticals Co

Inventors

• Sexton Daniel J
• Viswanathan Malini

Classifications

• A61P19/00

  Drugs for skeletal disorders · CPC title

• C07K16/40 Primary

  against enzymes · CPC title

• C07K2317/56

  variable (Fv) region, i.e. VH and/or VL · CPC title

• A61P19/06

  Antigout agents, e.g. antihyperuricemic or uricosuric agents · CPC title

• G01N2500/04

  Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A) · CPC title